Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Depreciation & Amortization (CF) (2016 - 2021)

Rhythm Pharmaceuticals (RYTM) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $201000.0 as the latest value for Q1 2021.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 20.36% to $201000.0 in Q1 2021 year-over-year; TTM through Dec 2021 was $201000.0, a N/A change, with the full-year FY2020 number at $690000.0, down 17.27% from a year prior.
  • Depreciation & Amortization (CF) was $201000.0 for Q1 2021 at Rhythm Pharmaceuticals, up from $172000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $245000.0 in Q1 2019 to a low of $54000.0 in Q1 2017.
  • A 5-year average of $138250.0 and a median of $169500.0 in 2020 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): soared 301.64% in 2019, then crashed 31.84% in 2020.
  • Rhythm Pharmaceuticals' Depreciation & Amortization (CF) stood at $60000.0 in 2017, then soared by 256.67% to $214000.0 in 2018, then dropped by 10.75% to $191000.0 in 2019, then dropped by 9.95% to $172000.0 in 2020, then increased by 16.86% to $201000.0 in 2021.
  • Per Business Quant, the three most recent readings for RYTM's Depreciation & Amortization (CF) are $201000.0 (Q1 2021), $172000.0 (Q3 2020), and $173000.0 (Q2 2020).